3 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Unresectable Malignant Neoplasm: new trials by email Literature Review of Unresectable Malignant Neoplasm trials Research Report on Unresectable Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemoradiotherapy in Unresectable Esophageal Cancer Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 105 | 2019-10-01 | 2024-12-13 |
| ImmunoPET With an Anti-CD8 Imaging Agent Anti-CD8 PET imaging agent - Metastatic Cancer, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Unknown | University Medical Center Groningen | 47 | 2019-02-14 | 2024-05-03 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-31 | 2025-02-21 | |
| A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Axatilimab, Durvalumab - Solid Tumor, Metastatic Tumor | Phase 1 | Completed | Syndax Pharmaceuticals | 45 | 2017-09-01 | 2024-05-17 |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer 18F-FHBG, Aldesleukin, Busulfan - HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 5 | 2017-07-26 | 2023-11-01 |
| Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 24 | 2016-03-01 | 2023-06-05 |
| Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery Ilorasertib, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm, Solid Neoplasm | Phase 1 | Completed | University of Chicago | 12 | 2015-09-08 | 2019-04-22 |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Sodium Bicarbonate - Tumor, Cancer | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2013-09-01 | 2015-06-04 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Carcinoma of Unknown Primary | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2011-06-20 | 2026-11-12 |
Neoplasm Metastasis (6) · Esophageal Neoplasms (2) · Breast Neoplasms (1) · Cancer Pain (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Liver Failure (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasms (1)
Neoplasms (8) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplasms by Histologic Type (4) · Neoplasms by Site (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplasms, Germ Cell and Embryonal (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Breast Diseases (1)
130-nm albumin-bound paclitaxel (1) · 9-(4-fluoro-3-hydroxymethylbutyl)guanine (1) · ALT-803 (1) · Albumin-Bound Paclitaxel (1) · Busulfan (1) · Carboplatin (1) · Cell- and Tissue-Based Therapy (1) · Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · ImmunityBio, Inc. (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Syndax Pharmaceuticals (1) · University Medical Center Groningen (1) · University of Chicago (1) · Wake Forest University Health Sciences (1)
United States (7) · China (1) · Netherlands (1)
Amit Mahipal, M.D. (1) · E. G.E. de Vries, MD, PhD (1) · Heidi Klepin (1) · Hussein A Tawbi (1) · Kate Madigan, MD (1) · Manish Sharma (1) · Theodore Scott Nowicki, M.D. (1) · Xin Wang, MD (1)
PMID 33867481, PMID 36271158, PMID 36452492, PMID 36471036, PMID 39704205, PMID 40593578
N01CM00100 (1), P30CA012197 (1), P30CA014599 (1), P30CA047904 (1), U01CA062490 (1), U01CA062502 (1), U01CA062505 (1), U01CA069856 (1), U01CA070095 (1), U01CA099168 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA186717 (1)